(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Aurora Cannabis, Canopy Growth, and BlackBerry.

The three biggest losers today are FibroGen, FuboTV, and Innodata.

Winners today

1. Aurora Cannabis (ACB) – 62.55%

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Leduc, Canada.

NYSE ended the session with Aurora Cannabis jumping 62.55% to $0.86 on Monday, after two successive sessions in a row of gains. NYSE rose 0.44% to $15,949.44, following the last session’s upward trend on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, Aurora Cannabis has a trailing twelve months EPS of $-6.5.

Volume

Today’s last reported volume for Aurora Cannabis is 185476000 which is 3555.26% above its average volume of 5074220.

More news about Aurora Cannabis.

2. Canopy Growth (CGC) – 56.15%

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flower, extracts and concentrates, beverages, gummies, and vapes. It offers its products under the Tweed, 7ACRES, 7ACRES Craft Collective, DOJA, Ace Valley, Quatreau, Deep Space, First + Free, Surity Pro, Spectrum Therapeutics, Vert, Tokyo Smoke, Twd, Martha Stewart CBD, DNA Genetics, BioSteel, Storz & Bickel, This Works, HiWay, Simple Stash, Whisl, and Truverra brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

NASDAQ ended the session with Canopy Growth jumping 56.15% to $1.46 on Monday, after two consecutive sessions in a row of gains. NASDAQ rose 1.14% to $13,917.89, following the last session’s upward trend on what was an all-around bullish trend trading session today.

Earnings Per Share

As for profitability, Canopy Growth has a trailing twelve months EPS of $-1.62.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -99.56%.

More news about Canopy Growth.

3. BlackBerry (BB) – 15.57%

BlackBerry Limited provides intelligent security software and services to enterprises and governments worldwide. The company operates through three segments: Cybersecurity, IoT, and Licensing and Other. The company offers CylancePROTECT, an endpoint protection platform and mobile threat defense solution; CylanceOPTICS, an endpoint detection and response solution; CylanceGUARD, a managed detection and response solution; CylanceGATEWAY, an AI-empowered zero-trust network access solution; CylancePERSONA, a user and entity behavior analytics solution; BlackBerry unified endpoint management, a central software component for secure communications platform; BlackBerry Dynamics, a development platform and secure container for mobile applications; and BlackBerry Workspaces solutions. It also provides BlackBerry SecuSUITE, a multi-OS voice and text messaging solution; BlackBerry AtHoc and BlackBerry Alert, which are secure and networked critical event management solutions; BlackBerry QNX that offers real-time operating systems, hypervisors, middleware, development tools, and professional services; BlackBerry Certicom, a cryptography and key management product; BlackBerry Radar, an asset monitoring solution; and BlackBerry IVY, an intelligent vehicle data platform. In addition, the company is involved in the patent licensing and legacy service access fees business. The company was formerly known as Research In Motion Limited and changed its name to BlackBerry Limited in July 2013. BlackBerry Limited was incorporated in 1984 and is headquartered in Waterloo, Canada.

NYSE ended the session with BlackBerry rising 15.57% to $5.27 on Monday while NYSE rose 0.44% to $15,949.44.

Earnings Per Share

As for profitability, BlackBerry has a trailing twelve months EPS of $-0.99.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BlackBerry’s stock is considered to be overbought (>=80).

Sales Growth

BlackBerry’s sales growth for the current quarter is negative 5.9%.

Volatility

BlackBerry’s last week, last month’s, and last quarter’s current intraday variation average was a negative 5.52%, a negative 0.13%, and a positive 2.60%.

BlackBerry’s highest amplitude of average volatility was 5.52% (last week), 3.48% (last month), and 2.60% (last quarter).

More news about BlackBerry.

4. BeiGene (BGNE) – 10.27%

BeiGene, Ltd., a biotechnology company, develops and commercializes oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; Tislelizumab to treat various solid tumor and blood cancers; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumor malignancies; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company is also developing Zanubrutinib to treat B-cell malignancies; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Ociperlimab for treating solid tumors, cervical cancer, and NSCLC; Surzebiclimab, BGB-A445, BGB-15025, Lifirafenib, BGB-24714, and BGB-B167 to treat solid tumors; BGB-10188 for treating solid tumors, B-cell lymphoid malignancies, and B-cell malignancies; BGB-11417 to treat R/R chronic lymphocytic leukemia/ small lymphocytic lymphoma, R/R mantle cell lymphoma, Mature B-cell malignancies, Myeloid malignancies, and R/R multiple myeloma; BGB-16673 for B-cell malignancies; and BGB-23339 for Inflammation and immunology. The company has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., Enlivex Therapeutics Ltd., Chime Biologics Limited, and Nanjing Leads Biolabs Co., Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

NASDAQ ended the session with BeiGene jumping 10.27% to $212.42 on Monday, after four consecutive sessions in a row of losses. NASDAQ jumped 1.14% to $13,917.89, following the last session’s upward trend on what was an all-around bullish trend trading session today.

Earnings Per Share

As for profitability, BeiGene has a trailing twelve months EPS of $-16.51.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -38.07%.

Moving Average

BeiGene’s value is above its 50-day moving average of $194.67 and below its 200-day moving average of $221.30.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BeiGene’s stock is considered to be overbought (>=80).

More news about BeiGene.

5. SNDL Inc. (SNDL) – 10%

SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through four segments: Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. The company also produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.

NASDAQ ended the session with SNDL Inc. jumping 10% to $2.15 on Monday, after two sequential sessions in a row of gains. NASDAQ rose 1.14% to $13,917.89, following the last session’s upward trend on what was an all-around up trend exchanging session today.

Earnings Per Share

As for profitability, SNDL Inc. has a trailing twelve months EPS of $-0.93.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -22.42%.

Moving Average

SNDL Inc.’s value is way above its 50-day moving average of $1.49 and way higher than its 200-day moving average of $1.83.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, SNDL Inc.’s stock is considered to be oversold (<=20).

More news about SNDL Inc..

6. Tilray (TLRY) – 9.67%

Tilray Brands, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. It also offers medical and adult-use cannabis products; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products. In addition, the company offers its products under the Tilray, Aphria, Broken Coast, Symbios, B!NGO, The Batch, Dubon, Good Supply, Solei, Chowie Wowie, Canaca, RIFF, SweetWater, Breckenridge Distillery, Alpine Beer Company, and Green Flash brands. It sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. and changed its name to Tilray Brands, Inc. in January 2022. Tilray Brands, Inc. is headquartered in Leamington, Canada.

NASDAQ ended the session with Tilray jumping 9.67% to $3.31 on Monday, following the last session’s upward trend. NASDAQ jumped 1.14% to $13,917.89, following the last session’s upward trend on what was an all-around positive trend trading session today.

Earnings Per Share

As for profitability, Tilray has a trailing twelve months EPS of $-2.38.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -37.14%.

More news about Tilray.

7. Tesla (TSLA) – 9.33%

Tesla, Inc. designs, develops, manufactures, leases, and sells electric vehicles, and energy generation and storage systems in the United States, China, and internationally. It operates in two segments, Automotive, and Energy Generation and Storage. The Automotive segment offers electric vehicles, as well as sells automotive regulatory credits; and non-warranty after-sales vehicle, used vehicles, retail merchandise, and vehicle insurance services. This segment also provides sedans and sport utility vehicles through direct and used vehicle sales, a network of Tesla Superchargers, and in-app upgrades; purchase financing and leasing services; services for electric vehicles through its company-owned service locations and Tesla mobile service technicians; and vehicle limited warranties and extended service plans. The Energy Generation and Storage segment engages in the design, manufacture, installation, sale, and leasing of solar energy generation and energy storage products, and related services to residential, commercial, and industrial customers and utilities through its website, stores, and galleries, as well as through a network of channel partners; and provision of service and repairs to its energy product customers, including under warranty, as well as various financing options to its solar customers. The company was formerly known as Tesla Motors, Inc. and changed its name to Tesla, Inc. in February 2017. Tesla, Inc. was incorporated in 2003 and is headquartered in Austin, Texas.

NASDAQ ended the session with Tesla rising 9.33% to $271.68 on Monday, after three successive sessions in a row of losses. NASDAQ rose 1.14% to $13,917.89, following the last session’s upward trend on what was an all-around positive trend trading session today.

Tesla shares can get to $400, says morgan stanley, citing AI opportunityIn our view, once Tesla makes headway on autonomy and software, third party Dojo services can offer investors the next leg of Tesla’s growth story., Shares of Tesla Inc. climbed in premarket trading on Monday after Morgan Stanley cheered an artificial-intelligence opportunity for the electric-vehicle company and became the most bullish analyst on its stock.

: U.S. stocks finish higher as Tesla propels S&P 500; dow rises third straight dayU.S. stocks closed higher Monday, with Tesla Inc. fueling the S&P 500 index’s gains while the Dow Jones Industrial Average rose for a third straight day.

Earnings Per Share

As for profitability, Tesla has a trailing twelve months EPS of $3.5.

PE Ratio

Tesla has a trailing twelve months price to earnings ratio of 77.62. Meaning, the purchaser of the share is investing $77.62 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 27.14%.

More news about Tesla.

8. NeuroMetrix (NURO) – 8.24%

NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.

NASDAQ ended the session with NeuroMetrix rising 8.24% to $0.79 on Monday, after two successive sessions in a row of losses. NASDAQ rose 1.14% to $13,917.89, following the last session’s upward trend on what was an all-around up trend trading session today.

Earnings Per Share

As for profitability, NeuroMetrix has a trailing twelve months EPS of $-0.7.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -24.14%.

Volatility

NeuroMetrix’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.07%, a negative 0.71%, and a positive 2.68%.

NeuroMetrix’s highest amplitude of average volatility was 2.64% (last week), 3.53% (last month), and 2.68% (last quarter).

Revenue Growth

Year-on-year quarterly revenue growth declined by 22.6%, now sitting on 7.2M for the twelve trailing months.

Moving Average

NeuroMetrix’s value is below its 50-day moving average of $0.86 and way under its 200-day moving average of $1.30.

Yearly Top and Bottom Value

NeuroMetrix’s stock is valued at $0.79 at 17:32 EST, way below its 52-week high of $3.57 and way above its 52-week low of $0.64.

More news about NeuroMetrix.

9. Lipocine (LPCN) – 8.06%

Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of metabolic and endocrine disorders. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase II Clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis (NASH); TLANDO XR, an oral prodrug of testosterone for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, an oral prodrug of bioidentical testosterone that has completed phase I clinical trial for the treatment of NASH cirrhosis; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.

NASDAQ ended the session with Lipocine jumping 8.06% to $3.99 on Monday while NASDAQ jumped 1.14% to $13,917.89.

Earnings Per Share

As for profitability, Lipocine has a trailing twelve months EPS of $-2.36.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -35.24%.

More news about Lipocine.

10. Clean Energy Fuels (CLNE) – 7.95%

Clean Energy Fuels Corp. provides natural gas as an alternative fuel for vehicle fleets and related fueling solutions in the United States and Canada. It supplies renewable natural gas (RNG), compressed natural gas (CNG), and liquefied natural gas (LNG) for medium and heavy-duty vehicles; and offers operation and maintenance services for public and private vehicle fleet customer stations. The company also designs, builds, operates, and maintains vehicle fueling stations; and sells and services compressors and other equipment that are used in RNG production and fueling stations. In addition, it transports and sells CNG, RNG, and LNG through virtual natural gas pipelines and interconnects; sells U.S. federal, state, and local government credits, such as RNG as a vehicle fuel, including Renewable Identification Numbers and Low Carbon Fuel Standards credits; and obtains federal, state, and local credits, grants, and incentives. Further, the company focuses on developing, owning, and operating dairy and other livestock waste RNG projects. It serves heavy-duty trucking, airports, refuse, public transit, industrial, and institutional energy users, as well as government fleets. As of December 31, 2022, the company served approximately 1,000 fleet customers operating approximately 50,000 vehicles. Clean Energy Fuels Corp. was incorporated in 2001 and is headquartered in Newport Beach, California.

NASDAQ ended the session with Clean Energy Fuels rising 7.95% to $4.75 on Monday while NASDAQ rose 1.14% to $13,917.89.

Earnings Per Share

As for profitability, Clean Energy Fuels has a trailing twelve months EPS of $-0.34.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -10.75%.

Volume

Today’s last reported volume for Clean Energy Fuels is 3400580 which is 120.64% above its average volume of 1541220.

More news about Clean Energy Fuels.

Losers Today

1. FibroGen (FGEN) – -14.31%

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

NASDAQ ended the session with FibroGen sliding 14.31% to $0.95 on Monday, after two consecutive sessions in a row of gains. NASDAQ jumped 1.14% to $13,917.89, following the last session’s upward trend on what was an all-around up trend trading session today.

Earnings Per Share

As for profitability, FibroGen has a trailing twelve months EPS of $-3.49.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -1015.79%.

More news about FibroGen.

2. FuboTV (FUBO) – -13.91%

fuboTV Inc. operates a live TV streaming platform for live sports, news, and entertainment content in the United States and internationally. Its fuboTV platform allows customers to access content through streaming devices, as well as on SmartTVs, computers, mobile phones, and tablets. The company is headquartered in New York, New York.

NYSE ended the session with FuboTV sliding 13.91% to $2.60 on Monday, after two consecutive sessions in a row of losses. NYSE rose 0.44% to $15,949.44, following the last session’s upward trend on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, FuboTV has a trailing twelve months EPS of $-1.75.

More news about FuboTV.

3. Innodata (INOD) – -8.79%

Innodata Inc. operates as a global data engineering company in the United States, the United Kingdom, the Netherlands, Canada, and internationally. The company operates through three segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment offers a range of solutions and platforms for solving data challenges that companies face when they seek to obtain the benefits of artificial intelligence systems and analytics platforms, including data annotation, data transformation, data curation, and intelligent automation. This segment also provides services for clients in the information industry that relate to content operations and product development. The Synodex segment offers an intelligent data platform that transforms medical records into useable digital data with its proprietary data models or client data models. The Agility segment provides an intelligent data platform that provides marketing communications and public relations professionals to target and distribute content to journalists and social media influencers; and to monitor and analyze global news channels, such as print, web, radio, and TV, as well as and social media channels. It serves banking, insurance, financial services, technology, digital retailing, and information/media sectors through its professional staff, senior management, and direct sales personnel. The company was formerly known as Innodata Isogen, Inc. and changed its name to Innodata Inc. in June 2012. Innodata Inc. was founded in 1988 and is headquartered in Ridgefield Park, New Jersey.

NASDAQ ended the session with Innodata dropping 8.79% to $10.06 on Monday, after five successive sessions in a row of losses. NASDAQ jumped 1.14% to $13,917.89, following the last session’s upward trend on what was an all-around positive trend trading session today.

Earnings Per Share

As for profitability, Innodata has a trailing twelve months EPS of $-0.27.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -40.84%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 1.7%, now sitting on 76.32M for the twelve trailing months.

More news about Innodata.

4. Infinity Pharmaceuticals (INFI) – -7.86%

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 1/1b clinical trials for the treatment of triple negative breast cancer, solid tumors, and ovarian cancer. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Cambridge, Massachusetts.

NASDAQ ended the session with Infinity Pharmaceuticals dropping 7.86% to $0.09 on Monday, after three sequential sessions in a row of losses. NASDAQ jumped 1.14% to $13,917.89, following the last session’s upward trend on what was an all-around bullish trend exchanging session today.

Earnings Per Share

As for profitability, Infinity Pharmaceuticals has a trailing twelve months EPS of $-0.42.

More news about Infinity Pharmaceuticals.

5. Virgin Galactic (SPCE) – -6.98%

Virgin Galactic Holdings, Inc. focuses on the development, manufacture, and operation of spaceships and related technologies for conducting commercial human spaceflight and flying commercial research and development payloads into space. It is also involved in the ground and flight testing, and post-flight maintenance of its spaceflight system vehicles. The company serves private individuals, researchers, and government agencies. Virgin Galactic Holdings, Inc. was founded in 2017 is headquartered in Las Cruces, New Mexico.

NYSE ended the session with Virgin Galactic dropping 6.98% to $2.13 on Monday, after five sequential sessions in a row of losses. NYSE rose 0.44% to $15,949.44, following the last session’s upward trend on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, Virgin Galactic has a trailing twelve months EPS of $-1.95.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -101.26%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Virgin Galactic’s stock is considered to be overbought (>=80).

Sales Growth

Virgin Galactic’s sales growth is 46% for the current quarter and 79.5% for the next.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Virgin Galactic’s EBITDA is -4.24.

Volatility

Virgin Galactic’s last week, last month’s, and last quarter’s current intraday variation average was a negative 3.04%, a negative 1.98%, and a positive 4.78%.

Virgin Galactic’s highest amplitude of average volatility was 3.04% (last week), 3.24% (last month), and 4.78% (last quarter).

More news about Virgin Galactic.

6. Aspen Group (ASPU) – -6.82%

Aspen Group, Inc., an education technology company, provides online higher education services in the United States. The company offers baccalaureate, master's, and doctoral degree programs in nursing and health sciences, business and technology, arts and sciences, and education fields through Aspen University and United States University. As of April 30, 2022, it had 13,334 degree-seeking students enrolled. Aspen Group, Inc. was founded in 1987 and is based in New York, New York.

NASDAQ ended the session with Aspen Group dropping 6.82% to $0.10 on Monday while NASDAQ jumped 1.14% to $13,917.89.

Earnings Per Share

As for profitability, Aspen Group has a trailing twelve months EPS of $-0.38.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -24.26%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 17.8%, now sitting on 70.92M for the twelve trailing months.

More news about Aspen Group.

7. Marathon (MARA) – -6.55%

Marathon Digital Holdings, Inc. operates as a digital asset technology company that mines digital assets with a focus on the blockchain ecosystem and the generation of digital assets in United States. The company was formerly known as Marathon Patent Group, Inc. and changed its name to Marathon Digital Holdings, Inc. in February 2021. Marathon Digital Holdings, Inc. was incorporated in 2010 and is headquartered in Fort Lauderdale, Florida.

NASDAQ ended the session with Marathon sliding 6.55% to $10.19 on Monday while NASDAQ jumped 1.14% to $13,917.89.

Earnings Per Share

As for profitability, Marathon has a trailing twelve months EPS of $-3.58.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -76.14%.

More news about Marathon.

8. MEI Pharma (MEIP) – -5.98%

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase II clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. The company has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and license agreements with Presage Biosciences, Inc. and CyDex Pharmaceuticals, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is headquartered in San Diego, California.

NASDAQ ended the session with MEI Pharma falling 5.98% to $5.19 on Monday, after two consecutive sessions in a row of gains. NASDAQ rose 1.14% to $13,917.89, following the last session’s upward trend on what was an all-around up trend exchanging session today.

Earnings Per Share

As for profitability, MEI Pharma has a trailing twelve months EPS of $-5.79.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -74.14%.

More news about MEI Pharma.

9. Riot Blockchain (RIOT) – -5.62%

Riot Platforms, Inc., together with its subsidiaries, operates as a bitcoin mining company in North America. It operates through Bitcoin Mining, Data Center Hosting, and Engineering segments. The company also provides co-location services for institutional-scale bitcoin mining companies; and critical infrastructure and workforce for institutional-scale miners to deploy and operate their miners. In addition, it engages in the design and manufacturing of power distribution equipment and custom engineered electrical products; electricity distribution product design, manufacture, and installation services primarily focused on large-scale commercial and governmental customers, as well as a range of markets, including data center, power generation, utility, water, industrial, and alternative energy; operation of data centers; and maintenance/management of computing capacity. The company was formerly known as Riot Blockchain, Inc. Riot Platforms, Inc. was incorporated in 1998 and is based in Castle Rock, Colorado.

NASDAQ ended the session with Riot Blockchain falling 5.62% to $10.34 on Monday, following the last session’s downward trend. NASDAQ rose 1.14% to $13,917.89, following the last session’s upward trend on what was an all-around positive trend exchanging session today.

Earnings Per Share

As for profitability, Riot Blockchain has a trailing twelve months EPS of $-1.54.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -21.82%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Riot Blockchain’s EBITDA is 5.9.

More news about Riot Blockchain.

10. Texas Pacific Land (TPL) – -5.51%

Texas Pacific Land Corporation engages in the land and resource management, and water services and operations businesses. The company's Land and Resource Management segment manages surface acres of land. This segment also holds own a 1/128th nonparticipating perpetual oil and gas royalty interest (NPRI) under approximately 85,000 acres of land; a 1/16th NPRI under approximately 371,000 acres of land; and approximately 4,000 additional net royalty acres located in the western part of Texas. In addition, this segment engages in easements and commercial leases activities, such as oil, gas and related hydrocarbons, power line and utility easements, and subsurface wellbore easements. Further, this segment leases its land for processing, storage, and compression facilities and roads; and is involved in sale of materials, such as caliche. Its Water Services and Operations segment provides full-service water offerings, including water sourcing, produced-water gathering/treatment, infrastructure development, and disposal solutions to operators in the Permian Basin. This segment also holds royalties for water sourced from its land. Texas Pacific Land Corporation was founded in 1888 and is headquartered in Dallas, Texas.

NYSE ended the session with Texas Pacific Land dropping 5.51% to $1,747.60 on Monday while NYSE jumped 0.44% to $15,949.44.

Earnings Per Share

As for profitability, Texas Pacific Land has a trailing twelve months EPS of $54.01.

PE Ratio

Texas Pacific Land has a trailing twelve months price to earnings ratio of 32.36. Meaning, the purchaser of the share is investing $32.36 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 54.35%.

Volatility

Texas Pacific Land’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.04%, a negative 0.21%, and a positive 1.72%.

Texas Pacific Land’s highest amplitude of average volatility was 2.14% (last week), 1.31% (last month), and 1.72% (last quarter).

More news about Texas Pacific Land.

Stay up to date with our winners and losers daily report